Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Profluent logo — Grounded in nature, authored by AI

Profluent

Grounded in nature, authored by AI

Founded 2022 United States Emeryville, United States 69 employees Series Unknown Total: $44.00M AI, Biotechnology

General Information

Company Name Profluent
Founded Year 2022
Location United States Emeryville, United States +1
Employees 69
Industries AI, Biotechnology
Funding Stage Series Unknown
Social

Get notified when Profluent moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

Profluent is strategically accelerating its commercialization and market penetration efforts following a substantial $35M venture round. Evidenced by active participation in major industry events like BIO and initiating discussions for key partnerships in AI protein design across various therapeutic areas, the company is poised for significant expansion. Coupled with ongoing hiring, these moves indicate a robust drive to leverage recent funding for growth and validate its AI-first approach in biomedicine.

Signal Types
Funding Hiring Business Development Market Expansion
Strategic Labels
Commercialization Drive Strategic Partnerships Team Expansion
Next Move: Partnerships
·
Impact: 9/10
·
Ideal For: AI Biotech Investors – Growth Stage

About Profluent

Profluent, a pioneering player in the intersection of AI and biotechnology, is making significant strides in revolutionizing protein design. Established in 2022, the company is based in Emeryville, CA, and has garnered support from top-tier investors including Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures.

Positioned as an AI-first protein design entity, Profluent utilizes deep generative models to create and validate novel proteins, with a vision to revolutionize biomedicine. Their slogan, "Grounded in nature, authored by AI," embodies their mission to decode the language of life using advanced technology.

The company's latest financial milestone was a $35.00M Venture Round investment secured on 21 March 2024, further cementing its potential in the industry. Notably, investors like Jeff Dean have shown confidence in Profluent, affirming its innovative approach and growth prospects.

Taxonomy: AI-first protein design, deep generative models, novel proteins, biomedicine revolution, functional protein design, protein validation, AI in biotech, gene editing, machine learning applications, biotech innovation, synthetic biology, life sciences, therapeutic protein development, biomedical research, computational biology

Services & Products

AI-authored Protein Solutions
CRISPR Gene Editing
Custom Protein Design
Biological Research and Development

Target Customers

Pharmaceutical Companies Agricultural Biotechnology Firms Industrial Biotech Manufacturers Research Institutions

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• 6
Investor Investor Investor Investor
•••• •••• 		21 Mar 2024
Seed Round •••••• 4
Investor Investor Investor Investor
25 Aug 2022

Profluent Alternatives & Competitors

View All Alternatives
Profluent vs
Cyrus Biotechnology
Cyrus Biotechnology United States

Discovering novel biologics using computational structure biology, AI, and massively parallel protei...

Series B
17 employees
Biotechnology, Nutrition
Compare Profluent vs Cyrus Biotechnology
Profluent vs
Celeris Therapeutics
Celeris Therapeutics United States

The PIC Engineering Company.

Series Unknown
1 employees
AI, Biotechnology
Compare Profluent vs Celeris Therapeutics
Profluent vs
Adaptyv
Adaptyv Switzerland

The cloud lab for protein designers

Series A
36 employees
Biotechnology, Pharmaceutical
Compare Profluent vs Adaptyv
View all alternatives

FAQ About Profluent

Grounded in nature, authored by AI
Profluent was founded in 2022.
Profluent is headquartered in Emeryville, United States.
Profluent operates in the following industries: AI, Biotechnology.
Profluent has approximately 69 employees.
Profluent has completed 2 funding rounds, raising a total of $44.00M. The latest funding stage is Series Unknown.
Profluent offers: AI-authored Protein Solutions, CRISPR Gene Editing, Custom Protein Design, Biological Research and Development.
Top alternatives and competitors to Profluent include Cyrus Biotechnology, Celeris Therapeutics, Adaptyv, ExpressionEdits, Superluminal Medicines Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Profluent and Cyrus Biotechnology are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Profluent and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy